

Insights into the genetic diversity of *Mycobacterium tuberculosis* in Tanzania

Liliana K. Rutaihwa^{1, 2, 3*}, Mohamed Sasamalo^{1, 2,3}, Aladino Jaleco^{1, 2}, Jerry Hella^{1, 2,3}, Ally Kingazi³, Lujeko Kamwela^{1, 2,3}, Amri Kingalu^{4, 5}, Bryceson Malewo^{4, 5}, Raymond Shirima^{4, 5}, Anna Doetsch^{1, 2}, Julia Feldmann^{1, 2}, Miriam Reinhard^{1, 2}, Sonia Borrell^{1, 2}, Klaus Reither^{1, 2}, Basra Doulla^{4, 5}, Lukas Fenner^{1, 2, 6#} and Sebastien Gagneux^{1, 2, *, #}

¹ Swiss Tropical and Public Health Institute, Basel, Switzerland

² University of Basel, Basel, Switzerland

³ Ifakara Health Institute, Bagamoyo, Tanzania

⁴ Central Tuberculosis Reference Laboratory, Dar es Salaam, Tanzania

⁵ National Tuberculosis and Leprosy Programme, Dar es Salaam, Tanzania

⁶ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

* Corresponding authors

Email: liliana.rutaihwa@gmail.com (LKR) and sebastien.gagneux@swisstph.ch (SG)

Equal contribution

Abstract

Background: Human tuberculosis (TB) is caused by seven phylogenetic lineages of the *Mycobacterium tuberculosis* complex (MTBC), Lineage 1–7. Recent advances in rapid genotyping of MTBC based on single nucleotide polymorphisms (SNP), allow for rapid and phylogenetically robust strain classification, paving the way for defining genotype-phenotype relationships in clinical settings. Such studies have revealed that, in addition to host and environmental factors, different strains of the MTBC influence the outcome of TB infection and disease. In Tanzania, such molecular epidemiological studies of TB however are scarce in spite of a high TB burden.

Methods and Findings: Here we used a SNP-typing method to genotype a nationwide collection of 2,039 MTBC clinical isolates obtained from new and retreatment TB cases diagnosed in 2012 and 2013. Four lineages, namely Lineage 1–4 were identified. The distribution and frequency of these lineages varied across the regions but overall, Lineage 4 was the most frequent (n = 866, 42.5%), followed by Lineage 3 (n = 681, 33.4%) and 1 (n = 336, 16.5%), with Lineage 2 being the least frequent (n = 92, 4.5%). A total of 64 (3.1%) isolates could not be assigned to any lineage. We found Lineage 2 to be associated with female sex (adjusted odds ratio [aOR] 2.25; 95% confidence interval [95% CI] 1.38 – 3.70, p < 0.001) and retreatment (aOR 1.78; 95% CI 1.00 – 3.02, p = 0.040). We found no associations between MTBC lineage and patient age or HIV status. Our sublineage typing based on spacer oligotyping revealed the presence of mainly EAI, CAS and LAM families. Finally, we detected low levels of multidrug resistant isolates among a subset of retreatment cases

44 **Conclusions:** This study provides novel insights into the influence of pathogen-related
45 factors on the TB epidemic in Tanzania.

46

Introduction

Tuberculosis (TB) is the leading cause of mortality due to an infectious disease [1]. In 2017, an estimated 10.0 million people developed TB globally, with 1.3 million dying of the disease. More than 80% of the TB burden lies in the thirty high burden countries [1]. Tanzania is among these countries, with a national average TB notification rate of 129 cases per 100,000; however, some regions show higher notification rates [2]. Like in most sub-Saharan African countries, the HIV epidemic contributes to the high TB incidence in Tanzania, where a-third of the TB patients are co-infected with HIV [2]. Contrarily, drug resistant-TB is still low in this setting [3]. Other risk factors such poverty also influence the epidemiology of TB in Tanzania [4].

Transmission of TB occurs via infectious aerosols, and upon exposure individuals can either develop active disease or remain latent infected [5]. It is estimated that a-quarter of the world's population is latently TB infected [6], with a 5 – 10% life time risk to develop active TB disease; this risk is 50% in case of HIV co-infected individuals [7].

The complex dynamics of TB infection and disease are determined by the environment, the host and the pathogen [8]. Seven main phylogenetic lineages of the *Mycobacterium tuberculosis* complex (MTBC) lineages (Lineage 1–7) are known to cause TB in humans [9]. These lineages are phylogeographically distributed, reflecting human migration histories and possibly adaptation to different human populations [10–12]. Some genomic differences among the MTBC strains translate into relevant biological and epidemiological phenotypes [13]. In general, strains of the globally distributed lineages, Lineage 2 and 4 or “generalists”, appear to be more virulent in average than those of the geographically restricted lineages,

Lineage 5 and 6 or “specialists” [9,13]. Epidemiologically speaking, these phenotypes are demonstrated by indicators such as transmission potential, disease severity and rate of progression from infection to disease [14–17].

Studying genotype-phenotype relationships requires understanding the genetic diversity of MTBC clinical strains in a given clinical setting. In Tanzania few studies have described the genetic diversity of MTBC [18–21]. These previous work revealed the presence of mainly three lineages; Lineage 1, 3 and 4, which include the EAI, CAS and LAM spoligo families, respectively. Lineage 2, which includes the Beijing family, has only been reported at the lowest frequencies. These previous studies are limited as they only focused on few geographical locations and used spacer oligonucleotide typing (spoligotyping) technique which has limitations for phylogenetically robust strain classification [22,23]. Only one study profiled MTBC on a countrywide scale albeit with low sampling coverage [20].

In this study we used for the first time a robust single nucleotide polymorphism (SNP) typing method to classify the largest so far nationwide collection of MTBC clinical isolates from Tanzania. We then looked for potential associations between the MTBC lineages and the clinical and epidemiological characteristics of the patients.

Material and Methods

Study setting

Our study was based on a nationwide convenience sample of sputum smear positive new and retreatment TB cases diagnosed between 2012 and 2013 in Tanzania. The collection was obtained via a platform established for routine TB drug resistance surveillance by the National Tuberculosis Leprosy Program (NTLP) of Tanzania, covering health facilities in all geographical regions of the country. Briefly, smear positive sputa specimens from approximately 25% of new TB cases (obtained by allocating four months of sample collection to each region annually) and from all retreatment cases were sent to zonal reference laboratories (i.e. Central Tuberculosis Reference Laboratory [CTRL] in Dar es Salaam, Bugando Medical Center [BMC] in Mwanza and Kilimanjaro Christian Medical Center [KCMC] in Kilimanjaro), which serve the respective nearby regions for culture. Isolates from the two zonal laboratories, BMC and KCMC were then sent to the CTRL for drug susceptibility testing (DST). For this study we used archived isolates obtained from the CTRL.

Study population and data collection

We included a total of 2,039 unique (single patient) culture-confirmed TB cases diagnosed between 2012 and 2013, each of whom we could retrieve the respective culture isolate. This study population represents 41% of all culture positive sputum samples processed and 1.6% of all TB notified cases in the country during the study period (S1 Fig). We also obtained corresponding socio-demographic and clinical information collected during patients' consultation at the respective health facilities. The demographic data collected included age, sex and geographical location of the patients, whereas clinical data included HIV status and disease category (i.e., new case and retreatment case).

Processing of culture isolates

The smear positive sputa samples were cultured on Löwenstein Jensen (LJ) growth medium according to laboratory protocols. For this study, we included *M. tuberculosis* clinical isolates retrieved from archived LJ media. We then prepared heat inactivated samples for the retrieved clinical isolates by suspending *M. tuberculosis* colonies into 1ml sterile water and heat inactivate at 95°C for one hour.

Molecular genotyping

We then classified the *M. tuberculosis* clinical isolates into main phylogenetic lineages by TaqMan real-time PCR according to standard protocols (Applied Biosystems, Carlsbad, USA) and as previously described [24]. We also performed 43-spacer spoligotyping on a membrane for a subset of representative *M. tuberculosis* clinical strains following standard protocols [25]. The clinical strains were assigned to spoligotype families using the online database SITVITWEB [26].

Drug Resistance Genotyping

We selected a subset of clinical isolates from retreatment cases to perform molecular drug resistance testing. We used a previously described multiplex polymerase chain reaction (PCR) to target the hotspot region of *rpoB* gene that confers resistance to rifampicin [27]. The PCR assay targets both the tuberculous and non-tuberculous *Mycobacteria* (MTBC and NTMs, respectively) *rpoB* gene, so we could also rule out the presence of non-tuberculous isolates in our study sample using the assay. The amplified *rpoB* gene product was confirmed by electrophoresis on a 2% agarose gel and sent for Sanger sequencing. We analyzed the resulting sequences by Staden software package [28] and using *M. tuberculosis* H37Rv *rpoB* gene as reference sequence.

132 **Statistical Analyses**

133 For statistical analyses we applied descriptive statistics to delineate patients' characteristics.

134 We used Chi-square or Fisher's exact tests for assessment of differences between groups in

135 categorical variables, whenever applicable. We used univariate and multivariate logistic

136 regression models to assess for the association between *M. tuberculosis* lineages and

137 patients' clinical and demographic characteristics. The associations were assessed for

138 Lineage 2 compared to all other lineages (Lineages 1, 3 and 4), adjusting for age, sex, disease

139 category and HIV status. All statistical analyses were performed in R 3.5.0 [29].

140

Results

Patients' demographic and clinical characteristics

The patients' demographic and clinical information in our study included; age, sex, geographical location, HIV and disease category (new or retreatment case). Table 1 describes patients' characteristics of the study population. The proportions of the observed and missing data for the study population are summarized in S2 Fig.

148 **Table 1.** Clinical and demographic characteristics of the TB cases

Characteristics	Valid Proportion %	Total (%) n = 2039
Age, median (IQR) 28 (20-38)		
Age groups (years)		
Child age (< 15)	9.87	193 (9.47)
Young age (15 - 24)	29.67	580 (28.45)
Early adult (25 - 44)	47.98	938 (46.00)
Late adult (45 - 64)	10.03	196 (9.61)
Old age (> 65)	2.46	48 (2.35)
Not available		84 (4.12)
	<i>total n = 1955</i>	
Sex		
Female	32.40	645 (31.63)
Male	67.60	1346 (66.01)
Not available		48 (2.35)
	<i>total n = 1991</i>	
HIV status		
Negative	67.71	1086 (53.26)
Positive	32.23	517 (25.36)
Indeterminate	0.06	1 (0.05)
Not available		435 (21.33)
	<i>total n = 1604</i>	
Patient category		
New case	83.95	1679 (82.34)
Retreatment	16.05	321 (15.74)
Not available		39 (1.91)
	<i>total n = 2000</i>	
Geographical zone		
Central	1.10	22 (1.08)
Coastal	51.55	1029 (50.47)
Lake	17.94	358 (17.56)
Northern	20.19	403 (19.76)
S. Highlands	8.12	162 (7.95)
Western	0.50	10 (0.49)
Zanzibar	0.60	12 (0.59)
Not available		43 (2.11)
	<i>total n = 1996</i>	

149 IQR, interquartile range

150 Our study population consisted of TB patients ranging between the age of 2 and 82 years
151 with a median age of 28 years (interquartile range [IQR] 20–38). To further probe the age
152 distribution in the study population, we categorized the TB patients into five different age

groups (Table 1). We detected approximately three-quarters of the TB cases to occur among the “young age” and “early adult” age groups. Our observation suggests that TB incidence in Tanzania like in other high burden settings [30] is largely contributed by ongoing transmission (rapid progression upon exposure to infection) as opposed to reactivation (longer latency). Further, our findings corroborate with the national TB notification rates in that about 10% of the TB cases are pediatric cases (< 15 years) [31].

Similar to other settings [1], we identified a higher proportion of male TB cases compared to female TB cases. However, the male-to-female ratio in our study population is higher than the national estimates for the two years of sampling (2.2:1 vs., 1.4:1). The striking gender imbalance among TB cases seems to peak at adolescence onwards and is less pronounced among pediatric TB cases (S1 Table). Additionally, a-third (32.2%, 517/1604) of the TB cases with available HIV status were HIV co-infected. In contrast TB/HIV co-infected cases were more likely to be female (44.5%, CI 38.3-50.7% vs., 25.8%, 95% CI 20.6-31.0%) which is consistent with HIV being generally more prevalent in females than males [32]. We found that our study population comprised 16.1% (321/2000) of TB retreatment cases, which was four-fold higher than the overall countrywide notifications [31]. Finally, more than half (51.6%, 1029/1996) of the TB patients in our study population were diagnosed in the Coastal zone of Tanzania and about 40% were either diagnosed in the Lake and Northern zones. In addition to higher TB notification rates, the three former mentioned geographical zones contain the country’s zonal TB reference laboratories. The remaining 10% of the patients were diagnosed in any of the remaining four geographical zones.

Main MTBC lineages in Tanzania

Using SNP-typing, we detected four of the seven known MTBC lineages (Fig 1), albeit at varying proportions. In our study setting, Lineage 4 and Lineage 3 were the most frequent (866, 42.5% and 681, 33.4%, respectively) followed by Lineage 1 (336, 16.5%). Lineage 2 was the least frequent (92, 4.5%). The remaining 64 clinical isolates (3.1%) could not be assigned into any of the MTBC lineages. Of the seven geographical zones, four (Coastal, Northern, Lake and Southern Highlands) were highly represented with more than 100 clinical strains each (Table 2). The distribution of the *M. tuberculosis* lineages varied within the geographical zones (Fig 1 and S3 Fig). Our findings reveal that Lineage 1 strains were more frequent in the Lake zone compared to the overall average frequency (20.9% vs. 16.8%), whereas the frequency of Lineage 3 in this zone was lower (27.6% vs. 34.3%) compared to other geographical zones. By contrast, Lineage 4 was the most predominant in all geographical zones and showed relatively similar frequencies across the zones.

Fig 1. MTBC lineages in Tanzania. A. MTBC lineage classification of 2,039 nationwide clinical strains. B. MTBC lineage frequencies and geographical distribution in Tanzania.

Table 2. *M. tuberculosis* lineage distribution across geographical regions in Tanzania

Geographical Zone	Lineage				Total
	L1 (%)	L2 (%)	L3 (%)	L4 (%)	
Central	8 (38.1)	2 (9.5)	4 (19)	7 (33.3)	21
Coastal	168 (16.8)	50 (5)	350 (35)	432 (43.2)	1000
Lake	72 (20.9)	12 (3.5)	95 (27.6)	165 (48)	344
Northern	52 (13.3)	22 (5.6)	145 (37)	173 (44.1)	392
S. Highlands	27 (16.9)	4 (2.5)	60 (37.5)	69 (43.1)	160
Western	0 (0)	1 (10)	4 (40)	5 (50)	10
Zanzibar	2 (18.2)	0 (0)	5 (45.5)	4 (36.4)	11
Total	329 (17)	91 (4.7)	663 (34.2)	855 (44.1)	1938

L1, Lineage 1; L2, Lineage 2; L3, Lineage 3; L4, Lineage 4

Sublineages

After we detected four main *M. tuberculosis* lineages, we next investigated the respective sublineages within Lineage 1, 3 and 4 using spoligotyping. Lineage 2 strains were excluded from this analysis since the global strains almost exclusively belong to one spoligotype family, Beijing with almost identical fingerprint pattern. We identified 24 spoligotypes (SITs) among the 107 clinical strains analyzed (S2 Table). Twenty six (24.3%) of the strains could not be assigned to any of the existing spoligotypes in the SITVITWEB database and therefore described as orphan spoligotypes. Several spoligotypes were identified within each of the three lineages. Lineage 1 strains mainly belonged to EAI5 spoligotype. On the other hand, CAS1_Kili was the most predominant spoligotype among the Lineage 3 strains. Within Lineage 4 strains, LAM, T, and H families were detected and expectedly the LAM sublineage, particularly LAM_ZWE was the most prevalent.

Associations between lineages and patients' characteristics

Having described the circulating main lineages of the *M. tuberculosis* we then assessed the relationship between the lineages and patients' characteristics (Table 3). We detected a higher proportion of female sex among TB patients infected with Lineage 2 (52.1%) compared to those infected with the other three lineages (range from 31% to 34.5%, $p = 0.009$). Moreover, we observed that retreatment cases were frequently infected with Lineage 2 strains (26.8%), which was twofold higher compared to Lineage 1 and 4 strains ($p < 0.001$). We found no evidence for association between lineages and patients' characteristics such as age and HIV status (Table 3).

Lineage 2 has previously been associated with retreatment cases, drug resistance and lately also with female sex [17,27]. We therefore investigated if similar associations exist in our study population using a subset of TB cases with complete clinical and demographic information ($n = 1515$). To assess these associations we performed logistic regression analyses comparing Lineage 2 to all other lineages pooled together (Table 4). Our analyses revealed Lineage 2 to be independently associated with female sex (adjusted odds ratio [aOR] 2.25; 95% confidence interval [95% CI] 1.38 – 3.70, $p < 0.001$) and retreatment cases (aOR 1.78; 95% CI 1.00 – 3.02, $p = 0.040$). We did not detect any association between the lineages and patients' age and the HIV status.

Table 3. Frequency distribution of *M. tuberculosis* main lineages across patients' characteristic groups

Patient characteristics	Lineage			
	L1, n (%)	L2, n (%)	L3, n (%)	L4, n (%)
Age group				
Child age (< 15)	25 (9.3)	5 (7)	55 (10.6)	71 (10.8)
Young age (15 - 24)	76 (28.4)	21 (29.6)	153 (29.4)	202 (30.8)
Early adult (25 - 44)	124 (46.3)	37 (52.1)	265 (50.99)	294 (44.9)
Late adult (45 - 64)	36 (13.4)	6 (8.5)	39 (7.5)	80 (12.29)
Old age (> 65)	7 (2.6)	2 (2.8)	9 (1.7)	8 (1.2)
Sex				
Female	83 (31)	37 (52.1)	180 (34.5)	220 (33.6)
Male	185 (69)	34 (47.9)	341 (65.5)	435 (66.49)
HIV status				
Negative	181 (67.5)	45 (63.4)	341 (65.5)	452 (69)
Positive	87 (32.5)	26 (36.6)	180 (34.5)	203 (31)
Patient category				
New case	232 (86.6)	52 (73.2)	400 (76.8)	558 (85.2)
Retreatment	36 (13.4)	19 (26.8)	121 (23.2)	97 (14.8)
Total	268 (17.7)	71 (4.7)	521 (34.4)	655 (43.2)

L1, Lineage 1; L2, Lineage 2; L3, Lineage 3; L4, Lineage 4

Table 4. Associations of patients' clinical and demographic characteristics with *M. tuberculosis* Lineage 2 (n = 71) compared to all other lineages (n = 1444)

Patient characteristics	Lineage 2	Unadjusted		Adjusted	
	n (%)	OR (95% CI)	p value	OR (95% CI)	p value
Age, median (IQR)	27 (20.5 – 38.5)			0.99 (0.98 – 1.01)	0.428
Female sex	37 (52.1)	2.17 (1.34–3.51)	0.002	2.25 (1.38 – 3.70)	<0.001
Retreatment case	19 (26.8)	1.71 (0.97–2.90)	0.052	1.78 (1.00 – 3.02)	0.040
HIV positive	26 (36.6)	0.98 (0.74 – 1.03)	0.915	1.03 (0.61 – 1.70)	0.91
Observations		1515		1515	

IQR, Interquartile range; OR, Odds ratio; 95% CI, 95% confidence interval.

Mutations within *rpoB* gene in retreatment cases

To investigate whether drug resistance was linked to a particular lineage, we included in total 145 retreatment cases for drug resistance genotyping of the *rpoB* gene that confers resistance to rifampicin. Out of these, 112 (77.2%) had no mutations compared to the H37Rv reference gene and 16 (11%) contained at least one mutation, either synonymous (3/16) or non-synonymous (13/16) (S4 Fig and S3 Table). We could not determine mutation status in the *rpoB* gene of 17 (11.7%) retreatment cases due to PCR and sequencing failure. Among the 13 strains detected with non-synonymous *rpoB* mutations, five belonged to Lineage 2, four to Lineage 4, three to Lineage 3 and one was unclassified (S4 Table). Table 4 summarizes the non-synonymous *rpoB* mutations detected.

242 **Table 4.** Detected mutations on the *rpoB* gene among the retreatment cases

rpoB mutation	Amino acid change	Comment
A1198G	T400A	reported
A1304T	D435V	reported
A1334T	H445L	reported
C1333G	H445D	reported
C1333T	H445Y	reported
T1289C	L430P	reported
A1442G	E481A	reported
C1294G	Q432E	reported
C1349T	S450L	reported

243

244

Discussion

In this study, we classified the countrywide collection of 2,039 *M. tuberculosis* isolates from smear positive new and retreatment TB cases diagnosed between 2012 and 2013 in Tanzania. Our findings show that the *M. tuberculosis* strains in Tanzania are diverse, comprising four main phylogenetic lineages (Lineage 1–4) which occur throughout the country. Specifically, we found that Lineage 4 was the most frequent nationwide, followed by Lineage 3 and 1. Despite Lineage 2's recent global dissemination [15], it was the least frequent in our study setting. Finally, our analysis on the relationship between *M. tuberculosis* lineages and patients' characteristics revealed associations of Lineage 2 with female sex and retreatment TB cases.

Among the 7 human-adapted MTBC lineages, Lineage 4 is the most broadly distributed and occurs at high frequencies in Europe, the Americas and Africa [26,33]. We observe that TB epidemics in Tanzania are also predominated by Lineage 4, which is regarded as the most successful of MTBC lineages [33]. In general, the wide geographical range of Lineage 4 is postulated to be driven by a combination of its enhanced virulence, high rates of human migration linked to its spread and ultimately its ability to infect different human population backgrounds [33,34]. In contrast, Lineage 1 and 3 are known to be mainly confined to the rim of the Indian Ocean [9], which is consistent with our observation that nearly 50% of the *M. tuberculosis* strains in Tanzania belong to these two lineages. This high prevalence of Lineage 1 and 3 likely reflects the long-term migrations between Eastern Africa and the Indian subcontinent [35]. In addition, the distribution and the frequency of Lineage 1 and 3 in the mainland away from the coast of Tanzania did not vary, suggesting spread via internal migrations. Lineage 1 was proposed to have evolved in East Africa prior disseminating out of the continent [12]. Based on this, one might expect higher frequencies of Lineage 1 in the

region. Instead, the so called “modern” (TbD1-) lineages (4 and 3 in this case) dominate in Tanzania despite presumably being introduced into the African continent only post-contact [33,36]. This illustrates the ability of “modern” lineages to thrive in co-existence with the pre-existing “ancient” (TbD1+) lineages such as Lineage 1 in our case, perhaps because of the comparably higher virulence [16,37]. The neighboring countries of Tanzania on the other hand show comparable *M. tuberculosis* lineage composition [38,39], indicating common demographic histories and ongoing exchanges that resulted into distinct *M. tuberculosis* populations. The frequency of Lineage 2–Beijing in Tanzania, like in most parts of the continent except for South Africa [38,39] is relatively low, despite the long-standing African-Asian contacts [39]. Evidence from recent studies show that Lineage 2–Beijing was only recently introduced into Africa [15,40].

The burden of TB disease is generally higher in males [1,41], rendering male sex as a potential risk factor for TB. Furthermore, the male bias among TB patients is also observed in settings with no obvious sex-based differences in health-seeking behavior [42]. Whilst we show similar trends in this study setting overall, our findings reveal that the proportion of females was higher among TB patients infected with Lineage 2. This finding is consistent with several other previous studies conducted in different settings [17,27,43]. Social and physiological factors predisposing males to higher risk of TB have been indicated [44]. On the one hand, these include risk behaviors such as substance abuse (alcoholism, tobacco smoking) and gender specific roles such as risk occupations (e.g., mining) that are male dominated and known to increase the risk for TB. On the other hand, genetic makeup and sex hormones might contribute to the differences in TB susceptibility among females and males, as epidemiological and experimental studies have suggested female sex hormones to be protective [44]. These observations would propose that the sex imbalance in TB to

emerge after the onset of puberty. Of note, we observe less sex imbalance in “child” age group (<15 years) which also corroborates the national notification rates [31]. However, this observation can be confounded by BCG vaccination which might be most effective in this age group. Despite the high prevalence of HIV among young females in sub-Saharan Africa [32] and HIV being the strongest risk factor for TB, TB burden remains higher in males. While social and physiological aspects play an important role, findings from this study and others previously conducted in Nepal and Vietnam [17,27] suggest that bacterial factors could disrupt the trends towards male bias in TB, a finding which warrants further investigation. Our hypothesis is that because of higher virulence, Lineage 2 strains are able to overcome the resistance poised by female sex which could explain the less pronounced sex imbalanced.

In addition to its association with female sex, Lineage 2 was also associated with retreatment TB cases [43]. A retreatment case in our study population represented recurrent TB case either due to relapse or reinfection. We hypothesized that this observation was possibly linked to drug resistance, given the previous reported association between Lineage 2 and drug resistance [45]. However, we detected only 9% (13/145) of strains among the retreatment subset tested to contain mutations conferring resistance to rifampicin, five of which belonged to Lineage 2. These findings would suggest that retreatment cases are mainly driven by reinfection as opposed to treatment failure or relapse.

Finally, as evidenced by the age distribution of TB cases in our study setting, recent or ongoing transmission in high burden countries is the main contributor to the TB burden rather than disease reactivation [30]. Additionally, an association with young age has been employed as an epidemiological proxy for highly transmissible strains and faster rates of disease progression [46,47]. In this study, we did not detect any differences in median age

of TB patients infected with different lineages (S5 Fig), an observation that could speak for high ongoing transmission rates in general, irrespective of lineage.

Our study is limited by focusing on a convenient collection of archived *M. tuberculosis* clinical isolates (representing 1.6% of all TB cases in 2012 and 2013) sampled from TB cases as part of countrywide drug resistance surveillance. Therefore, the strength or lack of associations between lineages and patients' characteristics could likely be affected by the sampling. In addition, most of the geographical zones were underrepresented which could in turn underestimate the respective regional lineage composition and the overall countrywide distribution. Systematic sampling would allow for better resolution on the distribution patterns, the frequencies and on epidemiological consequences of *M. tuberculosis* lineages, which might partially determine the regional specific epidemics.

In conclusion, this study addresses the countrywide *M. tuberculosis* population structure based on SNP-typing. We show that *M. tuberculosis* population in Tanzania is diverse with four of the seven known lineages detected. This study sets the stage for further in depth investigations on epidemiological impact of *M. tuberculosis* lineages in Tanzania.

333 **Acknowledgements**

334 We would like to thank the National Tuberculosis Leprosy Programme (NTLP) through the
335 Central Reference Laboratory (CTRL) for permission to use the *M. tuberculosis* isolate
336 collection for this study.

337

References

1. WHO. Global tuberculosis report. Geneva: World Health Organization. 2017.
2. National Tuberculosis and Leprosy Programme (NTLP). Annual report for 2016. Dar es Salaam. 2016;1–48.
3. Nagu TJ, Aboud S, Mwiru R, Matee M, Fawzi W, Mugusi F. Multi Drug and Other Forms of Drug Resistant Tuberculosis Are Uncommon among Treatment Naïve Tuberculosis Patients in Tanzania. Surolia A, editor. PLoS One. 2015 Apr 7;10(4):e0118601.
4. Ministry of Health and Social Welfare . Dar es Salaam. First tuberculosis prevalence survey in the United Republic of Tanzania. 2013;
5. Rieder HL. Epidemiologic Basis of Tuberculosis Control First edition 1999. 1999.
6. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. Metcalfe JZ, editor. PLOS Med. 2016 Oct 25;13(10):e1002152.
7. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature. 2011 Jan 27;469(7331):483–90.
8. Comas I, Gagneux S. The Past and Future of Tuberculosis Research. Manchester M, editor. PLoS Pathog. 2009;5(10):e1000600.
9. Gagneux S. Ecology and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol. 2018 Feb 19;16(4):202–13.
10. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci. 2006 Feb 21;103(8):2869–73.
11. Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, et al. HIV Infection Disrupts the Sympatric Host–Pathogen Relationship in Human Tuberculosis. Gibson G, editor. PLoS Genet. 2013 Mar 7;9(3):e1003318.
12. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013 Oct 1;45(10):1176–82.
13. Coscolla M. Biological and Epidemiological Consequences of MTBC Diversity. In: Strain variation in the Mycobacterium tuberculosis complex:Its role in biology, epidemiology and control. Springer, Cham; 2017. p. 95–116.
14. Hanekom M, van der Spuy GD, Streicher E, Ndabambi SL, McEvoy CRE, Kidd M, et al. A Recently Evolved Sublineage of the Mycobacterium tuberculosis Beijing Strain Family Is Associated with an Increased Ability to Spread and Cause Disease. J Clin Microbiol. 2007 May 1;45(5):1483–90.
15. Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, et al. Recent and Rapid Emergence of W-Beijing Strains of Mycobacterium tuberculosis in Cape Town, South

- 375 Africa. Clin Infect Dis. 2008 Nov 15;47(10):1252–9.
- 376 16. Stavrum R, PrayGod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, et
377 al. Increased level of acute phase reactants in patients infected with modern
378 Mycobacterium tuberculosis genotypes in Mwanza, Tanzania. BMC Infect Dis. 2014
379 Dec 5;14(1):309.
- 380 17. Holt KE, McAdam P, Thai PVK, Thuong NTT, Ha DTM, Lan NN, et al. Frequent
381 transmission of the Mycobacterium tuberculosis Beijing lineage and positive selection
382 for the EsxW Beijing variant in Vietnam. Nat Genet. 2018 Jun 21;50(6):849–56.
- 383 18. Eldholm V, Matee M, Mfinanga SGM, Heun M, Dahle UR. A first insight into the
384 genetic diversity of Mycobacterium tuberculosis in Dar es Salaam, Tanzania, assessed
385 by spoligotyping. BMC Microbiol. 2006 Sep 13;6(1):76.
- 386 19. Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, et al. M. tuberculosis
387 genotypic diversity and drug susceptibility pattern in HIV- infected and non-HIV-
388 infected patients in northern Tanzania. BMC Microbiol. 2007 May 31;7(1):51.
- 389 20. Mfinanga SGM, Warren RM, Kazwala R, Kahwa A, Kazimoto T, Kimaro G, et al. Genetic
390 profile of Mycobacterium tuberculosis and treatment outcomes in human pulmonary
391 tuberculosis in Tanzania. Tanzan J Health Res. 2014 Apr;16(2):58–69.
- 392 21. Mbugi E V., Katale BZ, Siame KK, Keyyu JD, Kendall SL, Dockrell HM, et al. Genetic
393 diversity of Mycobacterium tuberculosis isolated from tuberculosis patients in the
394 Serengeti ecosystem in Tanzania. Tuberculosis. 2015 Mar;95(2):170–8.
- 395 22. Comas I, Homolka S, Niemann S, Gagneux S. Genotyping of Genetically Monomorphic
396 Bacteria: DNA Sequencing in Mycobacterium tuberculosis Highlights the Limitations of
397 Current Methodologies. Litvintseva AP, editor. PLoS One. 2009 Nov 12;4(11):e7815.
- 398 23. Fenner L, Malla B, Ninet B, Dubuis O, Stucki D, Borrell S, et al. “Pseudo-Beijing”:
399 Evidence for Convergent Evolution in the Direct Repeat Region of Mycobacterium
400 tuberculosis. Sechi LA, editor. PLoS One. 2011 Sep 13;6(9):e24737.
- 401 24. Stucki D, Malla B, Hostettler S, Huna T, Feldmann J, Yeboah-Manu D, et al. Two New
402 Rapid SNP-Typing Methods for Classifying Mycobacterium tuberculosis Complex into
403 the Main Phylogenetic Lineages. Mokrousov I, editor. PLoS One. 2012 Jul
404 20;7(7):e41253.
- 405 25. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al.
406 Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for
407 diagnosis and epidemiology. J Clin Microbiol. 1997 Apr;35(4):907–14.
- 408 26. Demay C, Liens B, Burguière T, Hill V, Couvin D, Millet J, et al. SITVITWEB – A publicly
409 available international multimarker database for studying Mycobacterium
410 tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol. 2012
411 Jun;12(4):755–66.
- 412 27. Malla B, Stucki D, Borrell S, Feldmann J, Maharjan B, Shrestha B, et al. First Insights
413 into the Phylogenetic Diversity of Mycobacterium tuberculosis in Nepal. Sola C, editor.
414 PLoS One. 2012 Dec 26;7(12):e52297.

- 415 28. Staden R. The Staden sequence analysis package. *Mol Biotechnol.* 1996 Jun;5(3):233–
416 41.
- 417 29. R Core Team. R: A Language and Environment for Statistical Computing. 2018.
- 418 30. Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, et al. The
419 transmission of Mycobacterium tuberculosis in high burden settings. *Lancet Infect Dis.*
420 2016;16(2):227–38.
- 421 31. National Tuberculosis and Leprosy Programme (NTLP). Annual report for 2013. Dar es
422 Salaam. 2013.
- 423 32. Hegdahl HK, Fylkesnes KM, Sandøy IF. Sex Differences in HIV Prevalence Persist over
424 Time: Evidence from 18 Countries in Sub-Saharan Africa. Faragher EB, editor. *PLoS*
425 *One.* 2016 Feb 3;11(2):e0148502.
- 426 33. Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, et al. Mycobacterium
427 tuberculosis lineage 4 comprises globally distributed and geographically restricted
428 sublineages. *Nat Genet.* 2016 Dec 31;48(12):1535–43.
- 429 34. Coscolla M, Gagneux S. Consequences of genomic diversity in Mycobacterium
430 tuberculosis. *Semin Immunol.* 2014 Dec;26(6):431–44.
- 431 35. O'Neill MB, Shockey AC, Zarley A, Aylward W, Eldholm V, Kitchen A, et al. Lineage
432 specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia.
433 *bioRxiv.* 2018 Aug 1;210161.
- 434 36. Comas I, Hailu E, Kiros T, Bekele S, Mekonnen W, Gumi B, et al. Population Genomics
435 of Mycobacterium tuberculosis in Ethiopia Contradicts the Virgin Soil Hypothesis for
436 Human Tuberculosis in Sub-Saharan Africa. *Curr Biol.* 2015 Dec 21;25(24):3260–6.
- 437 37. Portevin D, Gagneux S, Comas I, Young D. Human Macrophage Responses to Clinical
438 Isolates from the Mycobacterium tuberculosis Complex Discriminate between Ancient
439 and Modern Lineages. Bessen DE, editor. *PLoS Pathog.* 2011 Mar 3;7(3):e1001307.
- 440 38. Mbugi E V., Katala BZ, Streicher EM, Keyyu JD, Kendall SL, Dockrell HM, et al. Mapping
441 of Mycobacterium tuberculosis Complex Genetic Diversity Profiles in Tanzania and
442 Other African Countries. Sreevatsan S, editor. *PLoS One.* 2016 May 5;11(5):e0154571.
- 443 39. Chihota VN, Niehaus A, Streicher EM, Wang X, Sampson SL, Mason P, et al. Geospatial
444 distribution of Mycobacterium tuberculosis genotypes in Africa. Arez AP, editor. *PLoS*
445 *One.* 2018 Aug 1;13(8):e0200632.
- 446 40. Rutaiwa LK, Menardo F, Stucki D, Gygli SM, Ley SD, Malla B, et al. Multiple
447 introductions of the Mycobacterium tuberculosis Lineage 2 Beijing into Africa over
448 centuries. *bioRxiv.* 2018 Sep 10;413039.
- 449 41. Guerra-Silveira F, Abad-Franch F. Sex Bias in Infectious Disease Epidemiology: Patterns
450 and Processes. Nishiura H, editor. *PLoS One.* 2013 Apr 24;8(4):e62390.
- 451 42. Rhines AS. The role of sex differences in the prevalence and transmission of
452 tuberculosis. *Tuberculosis.* 2013 Jan 1;93(1):104–7.

43. Buu TN, Huyen MN, Lan NTN, Quy HT, Hen N V, Zignol M, et al. The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. *Int J Tuberc Lung Dis*. 2009 Jul;13(7):900–6.
44. Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to Tuberculosis. *J Infect Dis*. 2014 Jul 15;209(suppl 3):S100–6.
45. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant *Mycobacterium tuberculosis* [State of the art]. *Int J Tuberc Lung Dis*. 2009;13(12):1456–1466.
46. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, Adetifa IM, et al. Progression to Active Tuberculosis, but Not Transmission, Varies by *Mycobacterium tuberculosis* Lineage in The Gambia. *J Infect Dis*. 2008 Oct 1;198(7):1037–43.
47. Borgdorff MW, van Soolingen D. The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? *Clin Microbiol Infect*. 2013 Oct;19(10):889–901.

467 **Supporting information**

468 **S1 Fig. Study population flowchart.**

469 **S2 Fig. Patients' data included in the study.** Proportion of observed and missing data for the
470 variables included in the study

471 **S3 Fig. MTBC lineage proportions.** Distribution of *M. tuberculosis* lineages across different
472 regions of Tanzania. Size of the circle is proportional to the number of isolates analyzed from
473 the regions.

474 **S4 Fig. Flowchart of genotyped strains for *rpoB* mutations.** A subset of *M. tuberculosis*
475 strains from retreatment cases included for *rpoB* drug resistance genotyping


476 **S5 Fig. Patients' age distribution across MTBC lineages.** The age distributions of TB patients
477 grouped by infecting MTBC lineage.

478 **S1 Table. Sex distribution across different age groups of TB patients.**

479 **S2 Table. Spoligotype patterns of a subset of *M. tuberculosis* clinical strains**

480 **S3 Table. Mutations detected in the *rpoB* gene**

481 **S4 Table. Distribution of *rpoB* mutations across the four MTBC lineages**



Figure